The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target?

Journal of Psychopharmacology

Volumn 24, Issue 4, 2010, Pages 455-469

  Rajkumar, Ramamoorthy ^a   Mahesh, Radhakrishnan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Antagonist; Behaviour; Depression; Postsynaptic; Serotonin type 3 receptor

Indexed keywords

8 HYDROXYLDIPROPYLAMINOTETRALIN; BEMESETRON; DESIPRAMINE; DOSULEPIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; IPRINDOLE; IPRONIAZID; KETAMINE; LEVODOPA; MIANSERIN; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NORFLUOXETINE; ONDANSETRON; PENTAGASTRIN; PHENELZINE; PINDOLOL; QUININE; SEROTONIN 1A AGONIST; SEROTONIN 3A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZACOPRIDE; ZATOSETRON;

AKATHISIA; ALCOHOLISM; ANXIETY DISORDER; BIPOLAR DISORDER; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DEPRESSION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FIBROMYALGIA; GENE EXPRESSION; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GILLES DE LA TOURETTE SYNDROME; HAMILTON SCALE; HEPATITIS C; HUMAN; HYPERACTIVITY; LOW DRUG DOSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PARKINSONISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL PHOBIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ANIMAL; NEURONS; POLYMORPHISM, GENETIC; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 77950445050     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109348161     Document Type: Review

References (210)

1. Adrien J., Tissier MH, Lanfumey L., et al. (1992) Central action of 5-HT3 receptor ligands in the regulation of sleepwakefulness and raphe neuronal activity in the rat. Neuropharmacology 31: 519-529.
2. Aina Y., Susman JL (2006) Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc 106: S9 - S14. (Pubitemid 44843771)
3. Ait-Daoud N., Johnson BA, Prihoda TJ, Hargita ID (2001) Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 154: 23-27. (Pubitemid 32186511)
4. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Therapeut 113: 296-320.
5. Anttila SAK, Leinonen EVJ (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7: 249-264. (Pubitemid 34016084)
6. Arnold LM (2008) Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiat 69: 14-19.
7. Bagdy E., Solyom S., Harsing LG, Jr (1998) Feedback stimulation of somatodendritic serotonin release: a 5-HT3 receptor-mediated effect in the raphe nuclei of the rat. Brain Res Bull 45: 203-208. (Pubitemid 28027805)
8. Barnes JM, Barnes NM, Costall B., Naylor RJ, Tyers MB (1989) 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 338: 762-763. (Pubitemid 19114378)
9. Barnes NM, Hales TG, Lummis SC, Peters JA (2009) The 5-HT3 receptor-the relationship between structure and function. Neuropharmacology 56: 273-284.
10. Barnes NM, Sharp T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152. (Pubitemid 29292403)
11. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., Benoliel JJ (2008) Repeated social defeat-induced depression-like behavioural and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatr 13: 1079-1092.
12. Belelli D., Balcarek JM, Hope AG, Peters JA, Lambert JJ, Blackburn TP (1995) Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol 48: 1054-1062. (Pubitemid 26009704)
13. Benloucif S., Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265: 373-377. (Pubitemid 23320984)
14. Berendsen HHG (1995) Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans ? Pharmacol Ther 66: 17-37.
15. Berendsen HHG, Broekkamp CL (1997) Indirect in vivo 5-HT1Aagonistic effects of the new antidepressant mirtazapine. Psychopharmacology 133: 275-282.
16. Berk M., Ichim C., Brook S. (2001) Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharm 16: 87-92. (Pubitemid 32171833)
17. Bhatnagar S., Nowak N., Babich L., Bok L. (2004) Deletion of the 5-HT3 receptor differentially affects behaviour of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res 153: 527-535. (Pubitemid 38953130)
18. Blandina P., Goldfarb J., Craddock-Royal B., Green JP (1989) Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 251: 803-809. (Pubitemid 20024888)
19. Blandina P., Goldfarb J., Walcott J., Green JP (1991) Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 256: 341-347.
20. Blier P., Bouchard C. (1993) Functional characterization of a 5-HT3 receptor which modulates the release of 5-HT in the guinea-pig brain. Brit J Pharmacol 108: 13-22. (Pubitemid 23007402)
21. Blier P., Monroe PJ, Bouchard C., Smith DL, Smith DJ (1993) 5-HT3 receptors which modulate [3H]5-HT release in the guinea-pig hypothalamus are not autoreceptors. Synapse 15: 143-148. (Pubitemid 23311585)
22. Bloom FE, Morales M. (1998) The central 5-HT3 receptor in CNS disorders. Neurochem Res 23: 653-659.
23. Boess FG, Beroukhim R., Martin IL (1995) Ultrastructure of the 5-hydroxytryptamine 3 receptor. J Neurochem 64: 1401-1405. Boess FG, Martin IL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33: 275-317.
24. Borsini F. (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav R 19: 377-395.
25. Borsini F., Cesana R., Vidi A., Mennini T. (1991) Evidence that imipramine activates 5-HT1C receptor function. Eur J Pharmacol 203: 359-363.
26. Bourin M., Hascoet M., Colombel MC, Redrobe JP, Baker GB (1996) Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Eur Neuropsychopharm 6: 231-236. (Pubitemid 26281562)
27. Bourin M., Redrobe JP, Baker GB (1998) Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology 136: 226-234. (Pubitemid 28143171)
28. Bradbury AJ, Costall B., Domeney AM, Naylor RJ (1985) Laterality of dopamine function and neuroleptic action in the amygdala in the rat. Neuropharmacology 24: 1163-1170. (Pubitemid 16182639)
29. Bradley PB, Engel G., Feniuk W., et al. (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563-576.
30. Brady CA, Dover TJ, Massoura AN, Princivalle AP, Hope AG, Barnes NM (2007) Identification of 5-HT3A and 5-HT3B receptor subunits in human hippocampus. Neuropharmacology 52: 1284-1290.
31. Braun DL, Sunday SR, Halmi KA (1994) Psychiatric comorbidity in patients with eating disorders. Psychol Med 24: 859-867.
32. Bravo G., Maswood S. (2006) Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test. Pharmacol Biochem Be 85: 362-368.
33. Brown AM, Hope AG, Lambert JJ, Peters JA (1998) Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol 507: 653-665.
34. Brüss M., Barann M., Hayer-Zillgen M., Eucker T., Göthert M., Bönisch H. (2000) Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor iso-forms. N-S Arch Pharmacol 362: 392-401.
35. Brüss M., Göthert M., Hayer M., Bönisch H. (1998) Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs. Ann NY Acad Sci 861: 234-235.
36. Bufton KE, Steward LJ, Barber PC, Barnes NM (1993) Distribution and characterization of the [3H] granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 32: 1325-1331.
37. Buskila D., Cohen H. (2007) Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep 11: 333-338.
38. Cameron OG (2006) Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions. Essent Psychopharmacol 7: 24-34.
39. Casper RC (1998) Depression and eating disorders. Depress Anxiety 8: 96-104.
40. Chau DT, Rada P., Kosloff RA, Taylor JL, Hoebel BG (2001) Nucleus accumbens muscarinic receptors in the control of behavioural depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. Neuroscience 104: 791-798.
41. Chen JP, van Praag HM, Gardner EL (1991) Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 543: 354-357.
42. Choi JS, Choi BH, Ahn HS, et al. (2003) Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells. Biochem Pharmacol 66: 2125-2132.
43. Costall B., Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Tyers MB (1987 a) Effects of the 5-HT3 receptor antagonists GR38032F, ICS 215-930 and BRL 43694 in tests for anxiolytic activity. Brit J Pharmacol 91: 195P.
44. Costall B., Domeney AM, Naylor RJ, Tyers MB (1987 b) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Brit J Pharmacol 92: 881-894.
45. Costall B., Naylor NJ (2004) 5-HT3 Receptors. Curr Drug Targets. CNS and Neurological Disorders 3: 27-37.
46. Costall B., Naylor RJ, Tyers MB (1990) The psychopharmacology of 5-HT3 receptors. Pharmacol Therapeut 47: 181-202.
47. Crespi D., Gobbi M., Mennini T. (1997) 5-HT3 serotonin hetero-receptors inhibit [3H] acethylcholine release in rat cortical synaptosomes. Pharmacol Res 35: 351-354.
48. Cryan JF, Valentino RJ, Lucki I. (2005) Assessing substrates underlying the behavioural effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav R 29: 547-569. (Pubitemid 40755456)
49. Davies PA, Pistis M., Hanna MC, et al. (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397: 359-363. (Pubitemid 29061650)
50. Davis L., Uezato A., Newell JM, Frazier E. (2008) Major depression and comorbid substance use disorders. Curr Opin Psychiatr 21: 14-18. (Pubitemid 351339802)
51. Dawes MA, Johnson BA, Ait-Daoud N., Ma JZ, Cornelius JR (2005 a) A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 30: 1077-1085. (Pubitemid 40745367)
52. Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N., Thomas SE, Cornelius JR (2005 b) Reductions in and relations between ĝ€ĝ€craving and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 30: 1630-1637. (Pubitemid 41443302)
53. De Deurwaerdere P., Moison D., Navailles S., Porras G., Spampinato U. (2005) Regionally and functionally distinct serotonin-3 receptors control in vivo dopamine outflow in the rat nucleus accumbens. J Neurochem 94: 140-149. (Pubitemid 40911400)
54. Delgado PL, Moreno FA (2000) Role of norepinephrine in depression. J Clin Psychiat 61: 5-12.
55. Dépôt M., Caillé G., Mukherjee J., Katzman MA, Cadieux A., Bradwejn J. (1999) Acute and chronic role of 5-HT3 neuronal system on behavioural and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 20: 177-187. (Pubitemid 29010376)
56. De Vry J., Melon C., Jentzsch K.R., Schreiber R. (1997) Identification of 5-HT receptor subtypes responsible for the therapeutic effects of selective 5-HT reuptake inhibitors (SSRIs). Biol Psychiatry 42: 67S - 68S.
57. Dilsaver SC (1986) Cholinergic mechanisms in depression. Brain Res 396: 285-316.
58. Dolnak DR (2006) Treating patients for comorbid depression, anxiety disorders, and somatic illnesses. J Am Osteopath Assoc 106: S1 - S8.
59. Dorostkar MM, Boehm S. (2007) Opposite effects of presynaptic 5-HT3 receptor activation on spontaneous and action potential-evoked GABA release at hippocampal synapses. J Neurochem 100: 395-405. (Pubitemid 46011000)
60. Doucet E., Miquel MC, Nosjean A., Verge ÂD, Hamon M., Emerit MB (2000) Immunolabeling of the rat central nervous system with antibodies partially selective of the short form of the 5-HT3 receptor. Neuroscience 95: 881-892.
61. Dremencov E., Weizmann Y., Kinor N., Gispan-Herman I., Yadid G. (2006) Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response. Curr Drug Targets 7: 165-175.
62. Dubin AE, Huvar R., DAndrea MR, et al. (1999) The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-HT3B receptor subunit. J Biol Chem 274: 30799-30810. (Pubitemid 129576826)
63. Edwards E., Hampton E., Ashby CR, Zhang J., Wang RY (1996) 5-HT3-like receptors in the rat medial prefrontal cortex: further pharmacological characterization. Brain Res 733: 21-30.
64. Eisensamer B., Rammes G., Gimpl G., et al. (2003) Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatr 8: 994-1007.
65. Eisensamer B., Uhr M., Meyr S., et al. (2005) Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J Neurosci 25: 10198-10206.
66. Epstein SA, Kay G., Clauw D., et al. (1999) Psychiatric disorders in patients with fibromyalgia A multicenter investigation. Psychosomatics 40: 57-63. (Pubitemid 29056581)
67. Fan P. (1994 a) Inhibition of a 5-HT3 receptor-mediated current by the selective serotonin uptake inhibitor, Fluoxetine. Neurosci Lett 173: 210-212. (Pubitemid 2090133)
68. Fan P. (1994 b) Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurons. Brit J Pharmacol 112: 741-744. (Pubitemid 24199076)
69. Fan P. (1994 c) Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine. Neuroscience 62: 515-522. (Pubitemid 2141929)
70. Färber L., Haus U., Späth M., Drechsler S. (2004) Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol 119: 2-8.
71. Faris PL, Eckert ED, Kim SW, et al. (2006) Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disorders 92: 79-90.
72. Faris PL, Kim SW, Meller WH, et al. (2000) Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomized, double-blind trial. Lancet 355: 792-797.
73. Fawcett J., Barkin RL (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disorders 51: 267-285. (Pubitemid 29202175)
74. Fernandez HH, Trieschmann ME, Friedman JH (2003) Treatment of psychosis in Parkinsons disease: safety considerations. Drug Safety 26: 643-659. (Pubitemid 36871837)
75. Fietta P., Manganelli P. (2007) Fibromyalgia and psychiatric disorders. Acta Bio-medica 78: 88-95.
76. Fletcher S., Barnes NM (1996) Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain. Brain Res 729: 281-284.
77. Fletcher S., Barnes NM (1998) Desperately seeking subunits: are native 5-HT3 receptors really homomeric complexes ? Trends Pharmacol Sci 19: 212-215. (Pubitemid 28312165)
78. Fletcher S., Barnes NM (1999) Autoradiographic localization of the [3H]-(S)-zacopride labelled 5-HT3 receptor in porcine brain. Neurosci Lett 269: 91-94. (Pubitemid 29335420)
79. Fonseca MI, Ni YG, Dunning DD, Miledi M. (2001) Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata. Brain Res. Mol Brain Res 89: 11-19. (Pubitemid 32322730)
80. Frank B., Niesler B., Nöthen MM, et al. (2004) Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B, Neuropsychiatr Genet 131: 1-5. (Pubitemid 39458429)
81. Friedberg G., Zoldan J., Weizman A., Melamed E. (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinsons disease. Clin Neuropharmacol 21: 280-284. (Pubitemid 28491427)
82. Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Brit J Pharm Chemoth 12: 323-328.
83. Galzin AM, Poncet V., Langer SZ (1990) 5-HT3 receptor agonists enhance the electrically-evoked release of [3H]-5-HT in guinea-pig frontal cortex slices. Brit J Pharmacol 101: 307P.
84. Gehlert DR, Gackenheimer SL, Wong DT, Robertson DW (1991) Localization of 5-HT3 receptors in the rat brain using [3H] LY278584. Brain Res 553: 149-154.
85. Geurts FJ, De Schutter E., Timmermans JP (2002) Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum. J Chem Neuroanat 24: 65-74. (Pubitemid 34655807)
86. Gilon P., Yakel JL (1995) Activation of 5-HT3 receptors expressed in Xenopus oocytes does not increase cytoplasmic Ca2+ levels. Receptor Channel 3: 83-88.
87. Giovannini MG, Ceccarelli I., Molinari B., Cecchi M., Goldfarb J., Blandina P. (1998) Serotonergic modulation of acetylcholine release from cortex of freely moving rats. J Pharmacol Exp Ther 285: 1219-1225. (Pubitemid 28277921)
88. Göthert M. (1990) Presynaptic serotonin receptors in the central nervous system. Ann NY Acad Sci 604: 102-112.
89. Grady TA, Broocks A., Canter SK, et al. (1996) Biological and behavioural responses to D-amphetamine, alone and in combination with the serotonin-3 receptor antagonist ondansetron, in healthy volunteers. Psychiat Res 64: 1-10. (Pubitemid 26298077)
90. Green T., Stauffer KA, Lummis SC (1995) Expression of recombinant homo-oligomeric 5-hydroxytryptamine3 receptors provides new insights into their maturation and structure. J Biol Chem 270: 6056-6061.
91. Greenshaw AJ (1993) Behavioural pharmacology of 5-HT3 receptor antagonist: A critical update on therapeutic potential. Trends Pharmacol Sci 141: 265-270.
92. Grunes MS, Yaryura-Tobias JA, Neziroglu FA (1996) Ondansetron in social phobia. Biol Psychiat 39: 624.
93. Gum AM, Cheavens JS (2008) Psychiatric comorbidity and depression in older adults. Curr Psychiatry Rep 10: 23-29. (Pubitemid 351266366)
94. Guo W., Todd K., Bourin M., Hascoet M., Kouadio F. (1996) Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol Biochem Be 54: 725-730. (Pubitemid 26258656)
95. Hagan RM, Butler A., Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987) Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 138: 303-305.
96. Hagan RM, Jones BJ, Jordan CC, Tyers MB (1990) Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Brit J Pharmacol 99: 227-232.
97. Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ (2006) 5HT3 antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology 186: 18-24.
98. Haus U., Späth M., Färber L. (2004) Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scand J Rheumatol 119: 12-18.
99. Haus U., Varga B., Stratz T., Späth M., Müller W. (2000) Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 113: 55-58.
100. Herzog DB, Keller MB, Sacks NR, Yeh CJ, Lavori PW (1992) Psychiatric comorbidity in treatment-seeking anorexics and bulimics. J Am Acad Child Psy 31: 810-818.
101. Hettema JM (2008) What is the genetic relationship between anxiety and depression? Am J Med Genet C, Semin Med Genet 148: 140-146.
102. Hewlett WA, Schmid SP, Salomon RM (2003) Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiat 64: 1025-1030.
103. Hope AG, Downie DL, Sutherland L., Lambert JJ, Peters JA, Burchell B. (1993) Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit. Eur J Pharmacol 245: 187-192.
104. Hoyer D. (1990) Serotonin 5-HT3, 5-HT4, and 5-HT-M receptors. Neuropsychopharmacology 3: 371-383.
105. Hoyer D., Gozlan H., Bolanos F., Schechter LE, Hamon M. (1989) Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact ? Eur J Pharmacol 171: 137-139.
106. Hoyer D., Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Be 71: 533-554.
107. Huang J., Spier AD, Pickel VM (2004) 5-HT3A receptor subunits in the rat medial nucleus of the solitary tract: subcellular distribution and relation to the serotonin transporter. Brain Res 1028: 156-169.
108. Imperato A., Puglisi-Allegra S., Zocchi A., Scrocco MG, Casolini P., Angelucci L. (1990) Stress activation of limbic and cortical dopamine release is prevented by ICS 205-930 but not by diazepam. Eur J Pharmacol 175: 211-214.
109. Invernizzi R., Pozzi L., Samanin R. (1995) Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU6215, a 5-HT3 receptor antagonist. Neuropharmacology 34: 211-215.
110. Isenberg KE, Ukhun IA, Holstad SG, et al. (1993) Partial cDNA cloning and NGF regulation of a rat 5-HT3 receptor subunit. Neuroreport 18: 121-124.
111. Jackson MB, Yakel JL (1995) The 5-HT3 receptor channel. Annu Rev Physiol 57: 447-468.
112. Jacocks HMI, Cox BM (1992) Serotonin-stimulated release of [3H] dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther 262: 356-364.
113. Jensen AA, Davies PA, Bräuner-Osborne H., Krzywkowski K. (2008) 3B but which 3B? And thats just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends Pharmacol Sci 29: 437-444.
114. Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept- an hypothesis. Alcohol Clin Exp Res 24: 1597-1601.
115. Johnson BA (2004) Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 18: 1105-1118.
116. Johnson BA, Ait-Daoud N., Elkashef AM, et al. (2008) A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychop 11: 1-14.
117. Johnson BA, Ait-Daoud N., Ma JZ, Wang Y. (2003) Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol Clin Exp Res 27: 1773-1779.
118. Johnson BA, Cowen PJ (1993) Alcohol-induced reinforcement: Dopamine and 5-HT3 receptor interactions in animals and humans. Drug Develop Res 30: 153-169.
119. Johnson BA, Roache JD, Ait-Daoud N., et al. (2006) A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depen 84: 256-263. (Pubitemid 44287214)
120. Johnson BA, Roache JD, Ait-Daoud N., Zanca NA, Velazquez M. (2002) Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology 160: 408-413. (Pubitemid 34253283)
121. Jones BJ, Costall B., Domeney AM, et al. (1988) The potential anxiolytic activity of GR 38032F, a 5-HT3 receptor antagonist. Brit J Pharmacol 93: 985-993. (Pubitemid 18093410)
122. Kankaanpaa A., Meririnne E., Seppala T. (2002) 5-HT3 receptor antagonist MDL72222 attenuates cocaine- and mazindol-, but not methylphenidate induced neurochemical and behavioural effects in the rat. Psychopharmacology 159: 341-350.
123. Kenney C., Kuo SH, Jimenez-Shahed J. (2008) Tourettes syndrome. Am Fam Physician 77: 651-658.
124. Kidd EJ, Laporte AM, Langlois X., et al. (1993) 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 612: 289-298. (Pubitemid 23167293)
125. Kilpatrick GJ, Butler A., Burridge J., Oxford AW (1990) 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist. Eur J Pharmacol 182: 193-197. (Pubitemid 20211603)
126. Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330: 746-748.
127. Kos T., Popik P., Pietraszek M., et al. (2006) Effect of 5-HT3 receptor antagonist MDL 72222 on behaviour induced by ketamine in rats and mice. Eur Neuropsychopharm 16: 297-310.
128. Koulu M., Sjoholm B., Lappalainen J., Virtanen R. (1989) Effects of acute GR38032F (Ondansetron). a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur J Pharmacol 169: 321-324. (Pubitemid 19253088)
129. Koyama S., Matsumoto N., Kubo C., Akaike N. (2000) Presynaptic 5-HT3 receptor-mediated modulation of synaptic GABA release in the mechanically dissociated rat amygdala neurons. J Physiol 529: 373-383. (Pubitemid 32007734)
130. Lankiewicz S., Lobitz N., Wetzel CHR, Rupprecht R., Gisselmann G., Hatt H. (1998) Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol 53: 202-212. (Pubitemid 28099729)
131. Laporte AM, Koscielniak T., Ponchant M., Verge D., Hamon M., Gozlan H. (1992) Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I] iodo-zacopride and [3H] zacopride as radioligands. Synapse 10: 271-281.
132. Lecrubier Y., Puech AJ, Azcona A., Bailey PE, Lataste XA (1993) Randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 112: 129-133. (Pubitemid 23261866)
133. Livesey MR, Cooper MA, Deeb TZ, et al. (2008) Structural determinants of Ca2+ permeability and conduction in the human 5-hydroxytryptamine type3A receptor. J Biol Chem 283: 19301-19313.
134. Lumia AR, Teicher MH, Salchli F., Ayers E., Possidente B. (1992) Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 587: 181-185.
135. Luscombe GP, Martin KF, Hutchins LJ, Gosden J., Heal DJ (1993) Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Brit J Pharmacol 108: 669-677. (Pubitemid 23067934)
136. McBride WJ, Lovinger DM, Machu T., et al. (2004) Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. Alcohol-Clin Exp Res 28: 257-267.
137. McCann UD, Morgan CM, Geraci M., Slate SO, Murphy DL, Post RM (1997) Effects of the 5-HT3 antagonist, ondansetron, on the behavioural and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 17: 360-369. (Pubitemid 27499923)
138. McNeish CS, Svingos AL, Hitzemann R., Strecker RE (1993) The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens. Pharmacol Biochem Be 45: 759-763. (Pubitemid 23213099)
139. Mahesh R., Perumal RV, Pandi PV (2005) Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Die Pharmazie 60: 83-96. (Pubitemid 40288700)
140. Mahesh R., Rajkumar R., Minasri B., Perumal RV (2007) Potential antidepressants: pharmacology of 2-(4-methyl piperazin-1-yl)-1, 8-naphthyridine-3-carbonitrile in rodent behavioural models. Die Pharmazie 12: 919-924. (Pubitemid 350305768)
141. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254: 432-437. (Pubitemid 21917361)
142. Martin KF, Hannon S., Phillips I., Heal DJ (1992 a) Opposing roles for 5-HT1B and 5-HT3 receptors in the control of 5-HT release in rat hippocampus in vivo. Brit J Pharmacol 106: 139-142.
143. Martin R., Gozlan H., Puech AJ (1992 b) 5-HT3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol 212: 73-78.
144. Mascagni F., McDonald AJ (2007) A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala. Neuroscience 144: 1015-1024. (Pubitemid 46013989)
145. Matsumoto M., Yoshioka M., Togashi H., Tochihara M., Ikeda T., Saito H. (1995) Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 272: 1044-1051.
146. Maura G., Andrioli GC, Cavazzani P., Raiteri M. (1992) 5-Hydroxytryptamine-3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J Neurochem 58: 2334-2337.
147. Miquel MC, Emerit MB, Gringrich JA, Nosjean A., Hamon M., el Mestikawy S. (1995) Developmental changes in the differential expression of two serotonin 5-HT3 receptor splice variants in the rat. J Neurochem 65: 475-483.
148. Miquel MC, Emerit MB, Nosjean A., Simon A., Rumajogee P., Brisorgueil MJ, Doucet E., Hamon M., Vergé D. (2002) Differential subcellular localization of the 5-HT3-As receptor subunit in the rat central nervous system. Eur J Neurosci 15: 449-457. (Pubitemid 35463663)
149. Mitchell EA, Pratt JA (1991) Neuroanatomical structures involved in the action of the 5-HT3 antagonist ondansetron: a 2-deoxyglucose autoradiographic study in the rat. Brain Res 538: 289-294.
150. Miyake A., Mochizuki S., Takemoto Y., Akuzawa S. (1995) Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 48: 407-416.
151. Morales M., Battenberg E., Bloom FE (1998) Distribution of neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord. J Comp Neurol 402: 385-401. (Pubitemid 28541686)
152. Morales M., Wang SD (2002) Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 22: 6732-6741. (Pubitemid 35386429)
153. Nakagawa Y., Ishima T., Takashima T. (1998) The 5-HT3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats. Brain Res 786: 189-193. (Pubitemid 28191729)
154. Nayak SV, Rondé P., Spier AD, Lummis SC, Nichols RA (2000) Nicotinic receptors colocalize with 5-HT3 serotonin receptors on striatal nerve terminals. Neuropharmacology 39: 2681-2690.
155. Newberry NR, Cheshire SH, Gilbert MJ (1991) Evidence that the 5HT3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different. Brit J Pharmacol 102: 615-620.
156. Niesler B., Flohr T., Nöthen MM, et al. (2001) Association between the 5ĝ€2 UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 11: 471-475. (Pubitemid 32778225)
157. Niesler B., Frank B., Kapeller J., Rappold GA (2003) Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310: 101-111. (Pubitemid 36703304)
158. Niesler B., Walstab J., Combrink S., et al. (2007) Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. Mol Pharmacol 72: 8-17.
159. Nutt DJ, Stein DJ (2006) Understanding the neurobiology of comorbidity in anxiety disorders. CNS Spectr 11: 13-20. (Pubitemid 44625550)
160. Offenbaecher M., Glatzeder K., Ackenheil M. (1998) Self-reported depression, familial history of depression and fibromyalgia (FM). and psychological distress in patients with FM. Z Rheumatol 57: 94-96. (Pubitemid 29011491)
161. Overstreet DH, Pucilowski O., Rezvani AH, Janowsky DS (1995) Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology 121: 27-37.
162. Palfreyman MG, Sorenson SM, Gittos MW, et al. (1996) Neurotherapeutic potential of 5-HT3 receptor antagonists. Eur Neuropsychopharm 6: S4.
163. Parker RMC, Barnes JM, Ge J., Barber PC, Barnes NM (1996) Autoradiographic distribution of [3H]-(S)-zacopride labelled 5HT3 receptors in human brain. J Neurol Sci 144: 119-127.
164. Peroutka SJ (1988 a) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 77: 496-500.
165. Peroutka SJ (1988 b) Species variations in 5-HT3 recognition sites labeled by 3H-quipazine in the central nervous system. N-S Arch Pharmacol 338: 472-475.
166. Perry DC (1990) Autoradiography of [3H]quipazine in rodent brain. Eur J Pharmacol 187: 75-85.
167. Peters JA, Lambert JJ (1989) Electrophysiology of 5-HT3 receptors in neuronal cell lines. Trends Pharmacol Sci 10: 172-175. (Pubitemid 19158370)
168. Peters JA, Malone HM, Lambert JJ (1992) Recent advances in the electrophysiological characterization of 5-HT3 receptors. Trends Pharmacol Sci 13: 391-397.
169. Piche T., Vanbiervliet G., Cherikh F., et al. (2005) Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 54: 1169-1173. (Pubitemid 41025915)
170. Porras G., De Deurwaerdere P., Moison D., Spampinato U. (2003) Conditional involvement of striatal serotonin 3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 17: 771-781. (Pubitemid 36315247)
171. Raiteri M., Paudice P., Vallebuona F. (1993) Release of cholecystokinin in the central nervous system. Neurochem Int 22: 519-527. (Pubitemid 223042450)
172. Ramamoorthy R., Radhakrishnan M., Borah M. (2008) Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 19: 29-40.
173. Rammes G., Eisensamer B., Ferrari U., et al. (2004) Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatr 9: 818. (Pubitemid 39273531)
174. Rammes G., Rupprecht R., Ferrari U., Zieglgänsberger W., Parsons CG (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306: 81-84. (Pubitemid 32524303)
175. Rasmussen K., Stockton ME, Czachura JF (1991) The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 205: 113-116.
176. Redrobe JP, Bourin M. (1997) Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 325: 129-135. (Pubitemid 27199561)
177. Redrobe JP, Pinot P., Bourin M. (1996) The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fund Clin Pharmacol 10: 524-528. (Pubitemid 26403134)
178. Richardson BP, Engel G. (1986) The pharmacology and function of 5-HT receptors. Trends Neurosci 9: 424-428.
179. Richardson BP, Engel G., Donatsch P., Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 376: 126-131. (Pubitemid 15073674)
180. Romach MK, Kaplan HL, Busto UE, Somer G., Sellers EM (1998) A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharm 18: 121-131. (Pubitemid 28192972)
181. Sambunaris A., Hesselink JK, Pinder R., Panagides J., Stahl SM (1997) Development of new antidepressants. J Clin Psychopharm 58: 40-53. (Pubitemid 27310168)
182. Santiago M., Machado A., Cano J. (1995) 5-HT3 receptor agonist induced carrier-mediated release of dopamine in rat striatum in vivo. Brit J Pharmacol 116: 1545-1550.
183. Sell LA, Cowen PJ, Robson PJ (1995) Ondansetron and opiate craving A novel pharmacological approach to addiction. Brit J Psychiat 166: 511-514.
184. Singer HS (2001) The treatment of tics. Curr Neurol Neurosci Rep 1: 195-202.
185. Sirota P., Mosheva T., Shabtay H., Giladi N., Korczyn AD (2000) Use of the selective serotonin3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiat 157: 287-289. (Pubitemid 30080916)
186. Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME (1999) Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharm 19: 125-131.
187. Sudweeks SN, Hooft JA, Yakel JL (2002) Serotonin 5-HT3 receptors in rat CA1 hippocampal interneurons: functional and molecular characterization. J Physiol 544: 715-726.
188. Sugita S., Shen KZ, North RA (1992) 5-hydroxytryptamine is a fast excitatory transmitter at 5-HT3 receptors in rat amygdala. Neuron 8: 199-203.
189. Tecott LH, Maricq AV, Julius D. (1993) Nervous system distribution of the serotonin 5-HT3 receptor mRNA. P Natl Acad Sci USA 90: 1430-1434.
190. Thompson AJ, Lummis SC (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Tar 11: 527-540.
191. Thompson AJ, Price KL, Reeves DC, Chan SL, Chau PL, Lummis SC (2005) Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding. J Biol Chem 280: 20476-20482.
192. Toren P., Laor N., Cohen DJ, Wolmer L., Weizman A. (1999) Ondansetron treatment in patients with Tourettes syndrome. Int Clin Psychopharm 14: 373-376.
193. Toren P., Weizman A., Ratner S., Cohen D., Laor N. (2005) Ondansetron treatment in Tourettes disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiat 66: 499-503.
194. Turkel SB, Nadala JGB, Wincor MZ (2001) Possible serotonin syndrome in association with 5-HT3 antagonist agents. Psychosomatics 42: 258-260.
195. Turner TJ, Mokler DJ, Luebke JI (2004) Calcium influx through presynaptic 5-HT3 receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. Neuroscience 129: 703-718.
196. Tzvetkov MV, Meineke C., Oetjen E., Hirsch-Ernst K., Brockmöller J. (2007) Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene 386: 52-62.
197. van Hooft JA, Vijverberg HPM (2000) 5-HT3 receptors and neurotransmitter release in the CNS: a nerve ending story ? Trends Neurosci 23: 605-610.
198. Varea E., Blasco-Ibántild;ez JM, Gómez-Climent MA, et al. (2007) Chronic fluoxetine treatment increases the expression of PSA-NCAM in the medial prefrontal cortex. Neuropsychopharmacology 32: 803-812.
199. Waeber C., Dixon K., Hoyer D., Palacios JM (1988) Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. Eur J Pharmacol 151: 351-352.
200. Werner P., Kawashima E., Reid J., et al. (1994) Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 26: 233-241.
201. West R., Hajek P. (1996) Randomised controlled trial of ondansetron in smoking cessation. Psychopharmacology 126: 95-96.
202. White A., Corn TH, Feetham C., Faulconbridge C. (1991) Ondansetron in treatment of schizophrenia. Lancet 337: 1173.
203. Wilde MI, Markham A. (1996) Ondansetron A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 52: 773-794.
204. Wolf H. (2000) Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 113: 37-45. (Pubitemid 32016435)
205. Wolters EC (1999) Dopaminomimetic psychosis in Parkinsons disease patients: diagnosis and treatment. Neurology 52: S10 - S13.
206. Wozniak KM, Pert A., Linnoila M. (1990) Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol 187: 287-289. (Pubitemid 20323953)
207. Yamada K., Hattori E., Iwayama Y., et al. (2006) Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiat 60: 192-201.
208. Yan D., Schulte MK, Bloom KE, White MM (1999) Structural features of the ligand-binding domain of the serotonin 5HT3 receptor. J Biol Chem 274: 5537-5541. (Pubitemid 29109202)
209. Zhang ZJ, Kang WH, Li Q., Wang XY, Yao SM, Ma AQ (2006) Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 88: 102-110. (Pubitemid 44693244)
210. Zoldan J., Friedberg G., Livneh M., Melamed E. (1995) Psychosis in advanced Parkinsons disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45: 1305-1308.